Sudha Sundar

ORCID: 0000-0002-5843-3015 · 11 papers in corpus
2026
BMJ (Clinical research ed.) ·doi:10.1136/bmj-2024-083912

ObjectiveTo investigate the accuracy of risk prediction models and scores for diagnosing ovarian cancer in premenopausal women presenting to secondary care with symptoms and abnormal test results.DesignProspective cohort study.SettingSecond…

2024
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society ·doi:10.1136/ijgc-2024-005332

ObjectivesPrimary mucinous ovarian carcinoma represents 3% of ovarian cancers and is typically diagnosed early, yielding favorable outcomes. This study aims to identify risk factors, focussing on the impact of age and ethnicity on survival …

2024
Essays in biochemistry ·doi:10.1042/ebc20240028

The ovaries are key steroid hormone production sites in post-pubertal females. However, current research on steroidogenic enzymes, endogenous hormone concentrations and their effects on healthy ovarian function and malignant development is …

2023
JMIR public health and surveillance ·doi:10.2196/41762

BackgroundOver-the-counter (OTC) medications are frequently used to self-care for nonspecific ovarian cancer symptoms prior to diagnosis. Monitoring such purchases may provide an opportunity for earlier diagnosis.ObjectiveThe aim of the Can…

2023
BMJ open ·doi:10.1136/bmjopen-2022-066022

ObjectivesOvarian cancer symptoms are often non-specific and can be normalised before patients seek medical help. The Cancer Loyalty Card Study investigated self-management behaviours of patients with ovarian cancer prior to their diagnosis…

2022
Cancers ·doi:10.3390/cancers14153621

Background: Ovarian cancer (OC) is a diagnostic challenge, with the majority diagnosed at late stages. Existing systematic reviews of diagnostic models either use inappropriate meta-analytic methods or do not conduct statistical comparisons…

2022
The Cochrane database of systematic reviews ·doi:10.1002/14651858.cd011964.pub2

BackgroundOvarian cancer (OC) has the highest case fatality rate of all gynaecological cancers. Diagnostic delays are caused by non-specific symptoms. Existing systematic reviews have not comprehensively covered tests in current practice, n…

2022
Cancers ·doi:10.3390/cancers14092124

Human epididymis 4 (HE4) is a promising ovarian cancer biomarker, but it has not been evaluated in primary care. In this prospective observational study, we investigated the diagnostic accuracy of HE4 alone and in combination with CA125 for…

2020
BMJ open ·doi:10.1136/bmjopen-2020-037459

IntroductionOvarian cancer is the eighth most common cancer in women worldwide, and about 1 in 5 women with ovarian cancer do not receive treatment, because they are too unwell by the time they are diagnosed. Symptoms of ovarian cancer are …

2020
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2019.07.031

BackgroundTransvaginal ultrasound and serum CA125 are routinely used for differential diagnosis of pelvic adnexal mass. Use of human epididymis 4 was approved in the United States in 2011. However, there is scarcity of studies evaluating th…

article 2007
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology ·doi:10.1080/01443610701362914

A 52-year-old woman presented with right loin and groin pain, a 5 cm homogenous right adnexal mass on ultrasound scan and an elevated CA125 of 188 IU/ml. She had previously undergone a hysterectomy...